165 related articles for article (PubMed ID: 3463774)
1. [Antibiotic activities of cefuzoname and the representative cephalosporins against clinically isolated methicillin resistant strains of Staphylococcus].
Arai T
Jpn J Antibiot; 1986 May; 39(5):1237-40. PubMed ID: 3463774
[TBL] [Abstract][Full Text] [Related]
2. Synergistic enhancement of in vitro antimicrobial activity of imipenem and cefazolin, cephalothin, cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus.
Uete T; Matsuo K
Jpn J Antibiot; 1995 Mar; 48(3):402-8. PubMed ID: 7752453
[TBL] [Abstract][Full Text] [Related]
3. [Fundamental and clinical studies on cefuzoname in the pediatric field].
Toyonaga Y; Sugita M; Kawamura K; Seo K; Takahashi T; Hori M
Jpn J Antibiot; 1987 Apr; 40(4):843-65. PubMed ID: 3613094
[TBL] [Abstract][Full Text] [Related]
4. Synergistic enhancement of in vitro antimicrobial activity of cefmetazole and cefazolin, cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus. I. Effect of NaCl.
Uete T; Matsuo K
Jpn J Antibiot; 1995 Apr; 48(4):553-62. PubMed ID: 7783318
[TBL] [Abstract][Full Text] [Related]
5. Synergistic enhancement of in vitro antimicrobial activity of cefmetazole and cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus. II. Effect of inoculum size.
Uete T; Matsuo K
Jpn J Antibiot; 1995 Apr; 48(4):563-70. PubMed ID: 7783319
[TBL] [Abstract][Full Text] [Related]
6. Ceftizoxime (FK 749) in vitro antibacterial activity.
Husson MO; Courcol R; Izard D; Leclerc H
Infection; 1984; 12(1):40-5. PubMed ID: 6323320
[TBL] [Abstract][Full Text] [Related]
7. [Susceptibility to cefazolin, cefamandole and ceftazidime in Staphylococcus strains].
Wiktorowicz-Belzyt E; Wojak I; Janicka G
Med Dosw Mikrobiol; 1997; 49(1-2):35-43. PubMed ID: 9411070
[TBL] [Abstract][Full Text] [Related]
8. Population analysis in strains of Staphylococcus aureus and Staphylococcus epidermidis. II. Cefuroxime and cefotaxime.
Hansen BG
Acta Pathol Microbiol Immunol Scand B; 1983 Dec; 91(6):425-9. PubMed ID: 6324530
[TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial activity of fosfomycin against beta-lactamase-producing methicillin-sensitive Staphylococcus aureus and methicillin-sensitive coagulase-negative staphylococci].
Hara T; Araake M; Tsuruoka T; Watabe H
Jpn J Antibiot; 2003 Apr; 56(2):142-7. PubMed ID: 12825415
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of sensitivity patterns of bacteria isolated from clinical materials to the 2d generation cephamycins and cephalosporins and clinical application of these antibiotics].
Matsuo K; Uete T
Jpn J Antibiot; 1983 Jul; 36(7):1621-37. PubMed ID: 6317908
[TBL] [Abstract][Full Text] [Related]
11. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
[TBL] [Abstract][Full Text] [Related]
12. Inoculum effect on growth-delay time of oxacillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis exposed to cefamandole, cefazolin, and cefuroxime.
Yourassowsky E; van der Linden MP; Crokaert F
Antimicrob Agents Chemother; 1990 Apr; 34(4):505-9. PubMed ID: 2344158
[TBL] [Abstract][Full Text] [Related]
13. [Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].
Okada K; Kawamura N; Ohkoshi M; Satake Y; Kawakita J
Jpn J Antibiot; 1982 Apr; 35(4):1009-21. PubMed ID: 6285019
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
[TBL] [Abstract][Full Text] [Related]
15. [Susceptibility of some bacteria isolated from clinical samples to third-generation cephalosporins].
Willke A; Tural D
Mikrobiyol Bul; 1987 Oct; 21(4):279-83. PubMed ID: 3332704
[TBL] [Abstract][Full Text] [Related]
16. Cephalosporin susceptibility of methicillin-resistant, coagulase-negative staphylococci.
Menzies RE; Cornere BM; MacCulloch D
Antimicrob Agents Chemother; 1987 Jan; 31(1):42-5. PubMed ID: 3646002
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of in vitro activity of first, second and third generation cephem antibiotics against various pathogens isolated from clinical materials in 1983].
Matsuo K; Tsuzaki Y; Furukawa S; Uete T
Jpn J Antibiot; 1984 Jun; 37(6):1040-57. PubMed ID: 6387213
[TBL] [Abstract][Full Text] [Related]
18. Optimal disk susceptibility testing of Staphylococcus epidermidis and aureus against penicillinase-resistant semisynthetic penicillins and cephalosporins.
Wybo I; Pierard D; Lauwers S
J Chemother; 1989 Jul; 1(4 Suppl):324-5. PubMed ID: 16312422
[No Abstract] [Full Text] [Related]
19. In vitro activity of cefotaxime against clinically significant pathogens.
Nakashio S; Nakamura M
Drugs; 1988; 35 Suppl 2():14-21. PubMed ID: 3260852
[TBL] [Abstract][Full Text] [Related]
20. [Experience of cefuzoname in pediatric patients. Fundamental and clinical investigations].
Kamiya H; Arai S; Kawai K; Ihara T; Sakurai M; Shimizu S; Kodama K; Iwasa T; Inoue M; Kojima M
Jpn J Antibiot; 1987 Apr; 40(4):867-82. PubMed ID: 3613095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
